345 related articles for article (PubMed ID: 16670247)
21. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
Dysken MW; Sano M; Asthana S; Vertrees JE; Pallaki M; Llorente M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Zachariah S; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Segal Y; Peduzzi PN; Guarino PD
JAMA; 2014 Jan; 311(1):33-44. PubMed ID: 24381967
[TBL] [Abstract][Full Text] [Related]
22. [Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil].
Creţu O; Szalontay AS; Chiriţă R; Chiriţă V
Rev Med Chir Soc Med Nat Iasi; 2008; 112(3):641-5. PubMed ID: 20201245
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
[TBL] [Abstract][Full Text] [Related]
25. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
[TBL] [Abstract][Full Text] [Related]
26. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J
Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135
[TBL] [Abstract][Full Text] [Related]
27. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
Gauthier S; Molinuevo JL
Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial.
Jia J; Wei C; Jia L; Tang Y; Liang J; Zhou A; Li F; Shi L; Doody RS
J Alzheimers Dis; 2017; 56(4):1495-1504. PubMed ID: 28157100
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
30. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Wilcock GK; Ballard CG; Cooper JA; Loft H
J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
Knapp M; King D; Romeo R; Adams J; Baldwin A; Ballard C; Banerjee S; Barber R; Bentham P; Brown RG; Burns A; Dening T; Findlay D; Holmes C; Johnson T; Jones R; Katona C; Lindesay J; Macharouthu A; McKeith I; McShane R; O'Brien JT; Phillips PPJ; Sheehan B; Howard R
Int J Geriatr Psychiatry; 2017 Dec; 32(12):1205-1216. PubMed ID: 27739182
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
33. Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R; McShane R; Lindesay J; Ritchie C; Baldwin A; Barber R; Burns A; Dening T; Findlay D; Holmes C; Hughes A; Jacoby R; Jones R; Jones R; McKeith I; Macharouthu A; O'Brien J; Passmore P; Sheehan B; Juszczak E; Katona C; Hills R; Knapp M; Ballard C; Brown R; Banerjee S; Onions C; Griffin M; Adams J; Gray R; Johnson T; Bentham P; Phillips P
N Engl J Med; 2012 Mar; 366(10):893-903. PubMed ID: 22397651
[TBL] [Abstract][Full Text] [Related]
34. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
[TBL] [Abstract][Full Text] [Related]
35. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Winblad B; Kilander L; Eriksson S; Minthon L; Båtsman S; Wetterholm AL; Jansson-Blixt C; Haglund A;
Lancet; 2006 Apr; 367(9516):1057-1065. PubMed ID: 16581404
[TBL] [Abstract][Full Text] [Related]
36. Rationalizing therapeutic approaches in Alzheimer's disease.
Grossberg GT
CNS Spectr; 2005 Nov; 10(11 Suppl 18):17-21. PubMed ID: 16273026
[TBL] [Abstract][Full Text] [Related]
37. Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials.
Tsoi KK; Hirai HW; Chan JY; Kwok TC
J Am Med Dir Assoc; 2016 Jan; 17(1):24-30. PubMed ID: 26392193
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
Doody RS; Geldmacher DS; Farlow MR; Sun Y; Moline M; Mackell J
Dement Geriatr Cogn Disord; 2012; 33(2-3):164-73. PubMed ID: 22572767
[TBL] [Abstract][Full Text] [Related]
39. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
40. Use of memantine for the treatment of dementia.
Lo D; Grossberg GT
Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
